Level Four Advisory Services’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $212K | Buy |
+1,657
| New | +$207K | 0.01% | 811 |
|
|
2025
Q3 | – | Sell |
-6,813
| Closed | -$565K | – | 834 |
|
|
2025
Q2 | $565K | Buy |
6,813
+50
| +0.7% | +$3.99K | 0.02% | 489 |
|
|
2025
Q1 | $548K | Buy |
6,763
+639
| +10% | +$57.1K | 0.02% | 478 |
|
|
2024
Q4 | $552K | Sell |
6,124
-223
| -4% | -$21.6K | 0.02% | 470 |
|
|
2024
Q3 | $616K | Sell |
6,347
-325
| -5% | -$31.9K | 0.03% | 460 |
|
|
2024
Q2 | $619K | Sell |
6,672
-878
| -12% | -$78.7K | 0.03% | 435 |
|
|
2024
Q1 | $674K | Hold |
7,550
| – | – | 0.04% | 380 |
|
|
2023
Q4 | $674K | Sell |
7,550
-906
| -11% | -$67.3K | 0.04% | 377 |
|
|
2023
Q3 | $617K | Buy |
8,456
+795
| +10% | +$63.5K | 0.04% | 386 |
|
|
2023
Q2 | $637K | Buy |
7,661
+622
| +9% | +$52K | 0.04% | 404 |
|
|
2023
Q1 | $536K | Sell |
7,039
-63
| -0.9% | -$5.23K | 0.04% | 408 |
|
|
2022
Q4 | $589K | Buy |
7,102
+508
| +8% | +$41.1K | 0.04% | 360 |
|
|
2022
Q3 | $523K | Buy |
6,594
+52
| +0.8% | +$4.38K | 0.05% | 305 |
|
|
2022
Q2 | $486K | Sell |
6,542
-231
| -3% | -$17.3K | 0.05% | 340 |
|
|
2022
Q1 | $609K | Sell |
6,773
-1,376
| -17% | -$127K | 0.05% | 341 |
|
|
2021
Q4 | $912K | Buy |
8,149
+301
| +4% | +$36.3K | 0.07% | 272 |
|
|
2021
Q3 | $987K | Sell |
7,848
-20,377
| -72% | -$2.62M | 0.1% | 192 |
|
|
2021
Q2 | $3.82M | Buy |
28,225
+1,980
| +8% | +$260K | 0.26% | 96 |
|
|
2021
Q1 | $3.56M | Buy |
26,245
+62
| +0.2% | +$9.28K | 0.28% | 93 |
|
|
2020
Q4 | $3.69M | Sell |
26,183
-10,717
| -29% | -$1.37M | 0.3% | 88 |
|
|
2020
Q3 | $4.11M | Sell |
36,900
-1,050
| -3% | -$118K | 0.32% | 73 |
|
|
2020
Q2 | $4.24M | Buy |
37,950
+13,179
| +53% | +$1.3M | 0.33% | 72 |
|
|
2020
Q1 | $1.92M | Buy |
24,771
+16,537
| +201% | +$1.46M | 0.23% | 112 |
|
|
2019
Q4 | $1.21M | Buy |
8,234
+11
| +0.1% | +$951 | 0.05% | 255 |
|
|
2019
Q3 | $627K | Buy |
8,223
+429
| +6% | +$35.7K | 0.06% | 288 |
|
|
2019
Q2 | $684K | Sell |
7,794
-1,183
| -13% | -$101K | 0.07% | 265 |
|
|
2019
Q1 | $813K | Buy |
8,977
+1,796
| +25% | +$153K | 0.09% | 226 |
|
|
2018
Q4 | $515K | Sell |
7,181
-2,528
| -26% | -$204K | 0.06% | 289 |
|
|
2018
Q3 | $931K | Sell |
9,709
-5,239
| -35% | -$508K | 0.1% | 206 |
|
|
2018
Q2 | $1.42M | Buy |
14,948
+1,289
| +9% | +$118K | 0.1% | 189 |
|
|
2018
Q1 | $1.2M | Buy |
13,659
+724
| +6% | +$66.1K | 0.09% | 200 |
|
|
2017
Q4 | $1.1M | Buy |
12,935
+370
| +3% | +$31K | 0.09% | 214 |
|
|
2017
Q3 | $1.09M | Buy |
12,565
+3,189
| +34% | +$256K | 0.1% | 200 |
|
|
2017
Q2 | $628K | Hold |
9,376
| – | – | 0.1% | 213 |
|
|
2017
Q1 | $628K | Buy |
9,376
+4,347
| +86% | +$292K | 0.06% | 276 |
|
|
2016
Q4 | $298K | Buy |
+5,029
| New | +$310K | 0.04% | 364 |
|
Other funds holding XBI
Level Four Advisory Services's XBI Position: Q1 2026 in Review
Level Four Advisory Services opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 1,657 shares worth $212K. The stake represents 0.01% of the portfolio and ranks #811 among its holdings. This is a return to the name: Level Four Advisory Services previously reported a position in XBI as recently as Q2 2025.
Level Four Advisory Services first reported a position in XBI in Q4 2016 and has held it in 36 quarters since. The position peaked at $4.24M in Q2 2020. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Level Four Advisory Services held 1,657 shares of State Street SPDR S&P Biotech ETF worth $212K as of Q1 2026.
- State Street SPDR S&P Biotech ETF was a new Level Four Advisory Services position in Q1 2026.
- State Street SPDR S&P Biotech ETF made up 0.01% of Level Four Advisory Services's portfolio in Q1 2026, its #811 holding.
- Level Four Advisory Services first reported a position in State Street SPDR S&P Biotech ETF in Q4 2016 and has held it in 36 quarters since.
- Level Four Advisory Services's State Street SPDR S&P Biotech ETF position peaked at $4.24M in Q2 2020.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Level Four Advisory Services's 13F filing for Q1 2026, filed 14 May 2026.